content: <HTML><HEAD>
  <TITLE>Form 8-K</TITLE>
  </HEAD>
    <BODY BGCOLOR="WHITE">
  
   <HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>SECURITIES AND EXCHANGE COMMISSION
  </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>Washington, D.C. 20549 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="17%" COLOR="#000000"><DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>FORM 8-K </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"
  COLOR="#000000"><B>CURRENT REPORT </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>Pursuant to Section 13 or 15(d) of the </B></FONT></DIV> <DIV
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>Securities Exchange Act of 1934 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Date of
  Report: December 2, 2002 </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Date of earliest event reported) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="6" COLOR="#000000"><B>INCYTE GENOMICS, INC. </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Exact name of registrant as specified in its charter) </B></FONT></DIV>
  <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="17%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Delaware</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>0-27488</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>94-3136539</B></FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(State or other jurisdiction</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>of
  incorporation)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Commission</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>File
  Number)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(IRS Employer</B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>Identification
  No.)</B></FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>3160 Porter Drive, Palo Alto, California 94304 </B></FONT></DIV> <DIV
  ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Address of principal executive offices) (Zip Code) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"
  COLOR="#000000"><B>Registrant&#146;s telephone number, including area code: (650) 855-0555 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Item 5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Events</U>. </FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">On December 2, 2002, Incyte Genomics, Inc. (the &#147;Company&#148;), Affymetrix, Inc. (&#147;Affymetrix&#148;) and The Board of Trustees of the Leland Stanford
  Junior University settled the following litigation matters: <I>Incyte Pharmaceuticals, Inc., et al. v. Affymetrix, Inc., </I>Case No. C99-21111 JF (N.D. Cal.), <I>Patrick O. Brown, et al. v. Stephen P.A. Fodor, et al.</I>, Patent Interference No.
  104,358 (Bd. of Patent App. and Inter.); <I>Patrick O. Brown, et al. v. Stephen P.A. Fodor, et al</I>., Patent Interference No. 104,359 (Bd. of Patent App. and Inter.), the Affymetrix Opposition to European Patent No. EP B 10804 731, and the
  Affymetrix opposition to Australian Patent No.&nbsp;AU709276 (2962/95). A final judgment was entered by Judge Fogel on December 4, 2002 in the <I>Incyte Pharmaceuticals, Inc., et al. v. Affymetrix, Inc., </I>Case No. C99-21111 JF (N.D. Cal.).
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">The final judgment provides, in part, that claims one through five of Affymetrix&#146;s United States Patent No. 5,800,992 (the
  &#147;&nbsp;&#146;992&nbsp;Patent&#148;) are invalid and that, therefore, there can be no interference between such &#146;992 Patent claims and certain claims of United States Patent Application No. 08/514,875 (the &#147;&nbsp;&#146;875
  Application&#148;), a patent application licensed by the Company from Stanford University, which will now be remanded to the Board of Patent Appeals and Interferences for further examination. The final judgment provides further, in part, that no
  interference in fact exists between certain claims in Affymetrix&#146;s United States Patent No.&nbsp;5,744,305 (the &#147;&nbsp;&#146;305 Patent&#148;) and certain claims set forth in United States Patent Application No. 08/688,488 (the
  &#147;&nbsp;&#146;488&nbsp;Application&#148;), a patent application licensed by the Company from Stanford University, which will now also be remanded to the Board of Patent Appeals and Interferences for further examination. There can be no
  assurances as to the outcome of the examination of the &#146;875 Application and &#146;488 Application. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">The settlement has no impact on
  the December 21, 2001, settlement by Affymetrix and the Company of then pending infringement claims asserted by each company against the other. All outstanding litigation matters between the Company and Affymetrix are now resolved and, accordingly,
  the Company expects to incur no further related litigation expense. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Except for the historical information contained herein, the matters
  set forth in this Current Report, including without limitation, statements as to the elimination of future litigation expenses, are forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities
  Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including without limitation, uncertainties associated with changes in patent laws, unexpected
  expenses related to the conclusion of the Company&#146;s litigation proceedings with Affymetrix, and other risks detailed from time to time in the Company&#146;s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended
  September 30, 2002. The Company disclaims any intent or obligation to update or revise these forward-looking statements. </FONT></DIV>
   <P></P> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">-2- </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
  
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>SIGNATURE </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Dated: December 9, 2002. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="right">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" COLSPAN="3" WIDTH="37%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">INCYTE GENOMICS, INC.</FONT></DIV> </TD> </TR>
  <TR>
  <TD HEIGHT="16"> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="2%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">By:</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="37%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">/s/&nbsp;&nbsp;&nbsp;&nbsp;Lee Bendekgey&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></DIV> <HR SIZE="1" NOSHADE
  COLOR="#000000" ALIGN="left"></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" ALIGN="center" WIDTH="37%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Lee Bendekgey</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Executive Vice President
  and</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">General Counsel</FONT></DIV> </TD> </TR>
   </TABLE> </DIV>
   <P></P> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">-3- </FONT></DIV>
  
   </BODY></HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 10605}]
metadata_filer: {"company-data": {"conformed-name": "INCYTE GENOMICS INC", "cik": "0000879169", "assigned-sic": "8731", "irs-number": "943136539", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-12400", "film-number": "02852884"}, "business-address": {"street1": "3160 PORTER DR", "city": "PALO ALTO", "state": "CA", "zip": "94304", "phone": "6508550555"}, "mail-address": {"street1": "3160 PORTER DRIVE", "city": "PALO ALTO", "state": "CA", "zip": "94304"}, "former-company": {"former-conformed-name": "INCYTE PHARMACEUTICALS INC", "date-changed": "19930902"}}
text: Form 8-K
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  Pursuant to Section 13 or 15(d) of the
  Securities Exchange Act of 1934
  Date of
  Report: December 2, 2002
  (Date of earliest event reported)
  INCYTE GENOMICS, INC.
  (Exact name of registrant as specified in its charter)
  Delaware
  0-27488
  94-3136539
  (State or other jurisdiction
  of
  incorporation)
  (Commission
  File
  Number)
  (IRS Employer
  Identification
  No.)
  3160 Porter Drive, Palo Alto, California 94304
  (Address of principal executive offices) (Zip Code)
  Registrant's telephone number, including area code: (650) 855-0555
  Item 5.
  Other Events
  .
  On December 2, 2002, Incyte Genomics, Inc. (the "Company"), Affymetrix, Inc. ("Affymetrix") and The Board of Trustees of the Leland Stanford
  Junior University settled the following litigation matters:
  Incyte Pharmaceuticals, Inc., et al. v. Affymetrix, Inc.,
  Case No. C99-21111 JF (N.D. Cal.),
  Patrick O. Brown, et al. v. Stephen P.A. Fodor, et al.
  , Patent Interference No.
  104,358 (Bd. of Patent App. and Inter.);
  Patrick O. Brown, et al. v. Stephen P.A. Fodor, et al
  ., Patent Interference No. 104,359 (Bd. of Patent App. and Inter.), the Affymetrix Opposition to European Patent No. EP B 10804 731, and the
  Affymetrix opposition to Australian Patent No. AU709276 (2962/95). A final judgment was entered by Judge Fogel on December 4, 2002 in the
  Incyte Pharmaceuticals, Inc., et al. v. Affymetrix, Inc.,
  Case No. C99-21111 JF (N.D. Cal.).
  The final judgment provides, in part, that claims one through five of Affymetrix's United States Patent No. 5,800,992 (the
  " '992 Patent") are invalid and that, therefore, there can be no interference between such '992 Patent claims and certain claims of United States Patent Application No. 08/514,875 (the " '875
  Application"), a patent application licensed by the Company from Stanford University, which will now be remanded to the Board of Patent Appeals and Interferences for further examination. The final judgment provides further, in part, that no
  interference in fact exists between certain claims in Affymetrix's United States Patent No. 5,744,305 (the " '305 Patent") and certain claims set forth in United States Patent Application No. 08/688,488 (the
  " '488 Application"), a patent application licensed by the Company from Stanford University, which will now also be remanded to the Board of Patent Appeals and Interferences for further examination. There can be no
  assurances as to the outcome of the examination of the '875 Application and '488 Application.
  The settlement has no impact on
  the December 21, 2001, settlement by Affymetrix and the Company of then pending infringement claims asserted by each company against the other. All outstanding litigation matters between the Company and Affymetrix are now resolved and, accordingly,
  the Company expects to incur no further related litigation expense.
  Except for the historical information contained herein, the matters
  set forth in this Current Report, including without limitation, statements as to the elimination of future litigation expenses, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities
  Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including without limitation, uncertainties associated with changes in patent laws, unexpected
  expenses related to the conclusion of the Company's litigation proceedings with Affymetrix, and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended
  September 30, 2002. The Company disclaims any intent or obligation to update or revise these forward-looking statements.
  -2-
  SIGNATURE
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.
  Dated: December 9, 2002.
  INCYTE GENOMICS, INC.
  By:
  /s/    Lee Bendekgey
  Lee Bendekgey
  Executive Vice President
  and
  General Counsel
  -3-